Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.